BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/1/2021 3:51:08 AM | Browse: 397 | Download: 1048
 |
Received |
|
2020-10-23 12:19 |
|
Peer-Review Started |
|
2020-10-23 12:19 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-11-20 07:41 |
|
Revised |
|
2020-12-24 16:40 |
|
Second Decision |
|
2021-01-07 12:05 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-01-07 17:49 |
|
Articles in Press |
|
2021-01-07 17:49 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-01-21 00:07 |
|
Typeset the Manuscript |
|
2021-02-24 06:15 |
|
Publish the Manuscript Online |
|
2021-03-01 03:51 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Case Report |
| Article Title |
Human menstrual-blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Juan Lu, Zhong-Yang Xie, Dan-Hua Zhu and Lan-Juan Li |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lan-Juan Li, FAASLD, Attending Doctor, Chairman, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79 Qing-chun Road, Hangzhou 310003, Zhejiang, China. ljli@zju.edu.cn |
| Key Words |
COVID-19; Human menstrual-blood-derived stem cells; Immunoregulatory therapy; Inflammatory response; Cytokine storm; Case report |
| Core Tip |
The coronavirus disease 2019 (COVID-19) is the word that certainly isn’t forgotten by everybody who lives in the first half of the twenty-first century.It has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, there is still no current effective guidance for the clinical management of COVID-19. Mesenchymal stem cells are widely used to treat tissue and organ injuries with effective immunomodulatory and repair capacities, which makes them ideal for allogenic adoptive transfer therapy. In this study, we describe the first confirmed case of COVID-19 in Hangzhou, China to explore the role of human menstrual blood-derived stem cells (MenSCs) in the treatment of COVID-19. Moreover, we review the immunomodulation effect including non-specific and specific immune functions of MenSCs for the therapy of COVID-19, which can be helpful to find a promisingly therapeutic approach for this disease. |
| Publish Date |
2021-03-01 03:51 |
| Citation |
Lu J, Xie ZY, Zhu DH, Li LJ. Human menstrual-blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of literature. World J Clin Cases 2021; 9(7): 1705-1713 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i7/1705.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i7.1705 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
